Innate Pharma SA (IPHA) stock

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30

$1.59+0.05 (+3.25%)

Close on Nov 11, 2026Market cap $149.01MP/E –Yield –

Innate Pharma gross margin

Gross margin is gross profit as a percentage of revenue.

Innate Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Innate Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IPHA.

Revenue growth-55.2% · median -38.4%

Operating margin-599.8% · median -1140.6%

Advertisement
300 × 250

See a number that looks wrong?